ArticleNature communications2023
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 3 pooled it
25.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 3 syntheses or guidelines pooled it, 126 citations in OpenAlex.
- Diagnostic biomarkers for α-synucleinopathies- state of the art and future developments: a systematic review.Molecular neurodegeneration · 2025Pooled it
- Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Pooled it
- Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Passive immunotherapy for Parkinson's disease in 2025: Status and perspective.Neural regeneration research · 2026Article
- Dopaminergic Radiopharmaceutical Imaging in Parkinsonian Syndromes: From Molecular Targets to Clinical Decision-Making.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Co- and Multi-Pathologies in Parkinson's Disease: An International Parkinson and Movement Disorder Society Scientific Issues Committee Review.Movement disorders : official journal of the Movement Disorder Society · 2026Review
- Neuropathological correlates of imaging in dementia with Lewy bodies.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Multiple system atrophy: cure and care.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- A Structure-Activity Relationship Study of Alpha Synuclein PET Radiotracer M503-1619.Molecules (Basel, Switzerland) · 2026Article
- Development and characterization of a novel TDP-43 positron emission tomography tracer: [Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Utility of Baseline Pathological, Neuroimaging and Clinical Markers for Prognosis in Early Parkinson's Disease.Journal of geriatric psychiatry and neurology · 2026Article
- Tracking Genetic Parkinson's Disease with Molecular Imaging: A Systematic Review.Movement disorders clinical practice · 2026Review
- Co-pathologies and biological processes beyond amyloid-beta and tau in people with Alzheimer's disease: Evidence from clinical cohort studies.Journal of internal medicine · 2026Review
- A Biological Framework for Parkinson's Disease: Advances in α-Synuclein-Centered Biomarkers and Staging.Journal of neurochemistry · 2026Review
- Autoradiography and preclinical PET studies with radiolabeled asyn-44 and ACI-12589 for imaging α-synuclein.Journal of Parkinson's disease · 2026Article
- From phenotype to biology: a multi-modal roadmap of biofluid, tissue, imaging, and digital biomarkers in Parkinson's disease.Translational neurodegeneration · 2026Review
- Neuroimaging in multiple system atrophy: clinical implications and novel developments.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Discordance of Dopaminergic Dysfunction and Subcortical Atrophy by α-Synuclein Status in Sporadic and Genetic Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- PET imaging of alpha-synuclein: from radiotracer design through in vitro and in vivo translation.European journal of nuclear medicine and molecular imaging · 2026Review
- The role of neuro-imaging in multiple system atrophy.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 7 institutions in 5 countries.
Ruben Smith *Clinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-7147-0112
Francesca Capotosti *AC Immune SA, EPFL Innovation Park, Building B, 1015, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-2819-3206
Martin SchainClinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden.
Tomas OhlssonDepartment of Radiation Physics, Skånes University Hospital, Lund, Sweden.
Efthymia VokaliAC Immune SA, EPFL Innovation Park, Building B, 1015, Lausanne, Switzerland.
Jerome MoletteAC Immune SA, EPFL Innovation Park, Building B, 1015, Lausanne, Switzerland.ORCID http://orcid.org/0009-0000-5381-5535
Tanja TouillouxAC Immune SA, EPFL Innovation Park, Building B, 1015, Lausanne, Switzerland.
Valerie HlivaAC Immune SA, EPFL Innovation Park, Building B, 1015, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-1252-0033
Ioannis K DimitrakopoulosAC Immune SA, EPFL Innovation Park, Building B, 1015, Lausanne, Switzerland.
Andreas PuschmannDepartment of Neurology, Skåne University Hospital, Lund, Sweden.
Jonas JögiDepartment of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund, Sweden.
Per SvenningssonDepartment of Neurology, Academic Specialist Center, Karolinska University Hospital, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-6727-3802
Mattias AndréassonDepartment of Neurology, Academic Specialist Center, Karolinska University Hospital, Stockholm, Sweden.
Christine SandiegoInvicro, LLC, New Haven, CT, USA.
David S RussellInvicro, LLC, New Haven, CT, USA.ORCID http://orcid.org/0000-0002-9105-2943
Patricia Miranda-AzpiazuClinical Neuroscience, PET Division, Karolinska Institute, Stockholm, Sweden.
Christer HalldinClinical Neuroscience, PET Division, Karolinska Institute, Stockholm, Sweden.
Erik StomrudClinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden.
Sara HallClinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0001-6585-9105
Klas BrattebyDepartment of Radiation Physics, Skånes University Hospital, Lund, Sweden.ORCID http://orcid.org/0000-0003-0930-2390
Elina Tampio L'EstradeDepartment of Radiation Physics, Skånes University Hospital, Lund, Sweden.
Ruth Luthi-CarterAC Immune SA, EPFL Innovation Park, Building B, 1015, Lausanne, Switzerland.
Andrea PfeiferAC Immune SA, EPFL Innovation Park, Building B, 1015, Lausanne, Switzerland.
Marie Kosco-VilboisAC Immune SA, EPFL Innovation Park, Building B, 1015, Lausanne, Switzerland.
Johannes StrefferAC Immune SA, EPFL Innovation Park, Building B, 1015, Lausanne, Switzerland. johannes.streffer@uantwerpen.be.ORCID http://orcid.org/0000-0002-9387-5951
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences, Malmö, Lund University, Lund, Sweden. Oskar.Hansson@med.lu.se.ORCID http://orcid.org/0000-0001-8467-7286
AC Immune (Switzerland) · CHLund University · SESkåne University Hospital · SEInvicro (United States) · USKarolinska Institutet · SEKarolinska University Hospital · SEUniversity of Antwerp · BE
Funding
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5MNational Brain and Tissue Resource for Parkinson's Disease and Related DisordersU24NS072026 · NINDS · BANNER SUN HEALTH RESEARCH INSTITUTE · PI BEACH, THOMAS G · 2011 to 2015
$7.8MNIA NIH HHS P30 AG019610NINDS NIH HHS U24 NS072026
Abstract
A positron emission tomography (PET) tracer detecting α-synuclein pathology will improve the diagnosis, and ultimately the treatment of α-synuclein-related diseases. Here we show that the PET ligand, [
Indexed as
Multiple System AtrophyParkinson Diseasealpha-SynucleinHumansPositron-Emission Tomographyalpha-Synuclein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.